Generic and biosimilar drugs saved the U.S. healthcare system $467 billion in 2024 and $3.4 trillion since 2015. These affordable alternatives make up 90% of prescriptions but only 12% of drug spending, cutting costs for patients, insurers, and government programs.
Read More